7 terminated. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Coronavirus: new trials by email Literature Review of Coronavirus trials Research Report on Coronavirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) Silmitasertib - Coronavirus | Phase 2 | Terminated | University of Arizona | 31 | 2021-01-21 | 2023-11-07 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 CYNK-001 - Coronavirus, Coronavirus Infection | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 7 | 2020-09-02 | 2026-06-26 |
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
| A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) PTC299, SOC, Placebo - Pneumonia, COVID-19 | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 189 | 2020-07-09 | 2023-06-26 |
| A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 SNDX-6352, Placebo - Coronavirus, COVID | Phase 2 | Terminated | Syndax Pharmaceuticals | 1 | 2020-05-30 | 2022-07-22 |
| Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial Plasma exchange, Standar medical treatmen - Coronavirus | Phase 2 | Terminated | Fundacion Clinic per a la Recerca Biomédica | 36 | 2020-04-29 | 2022-04-05 |
| PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine Group 1 HCQ, Group 2 Placebo - Coronavirus, Corona Virus Infection | Phase 2 | Terminated | UnitedHealth Group | 39 | 2020-04-07 | 2021-10-19 |
Coronavirus Infections (7) · COVID-19 (4) · Pneumonia (3) · Cytokine Release Syndrome (2) · Cardiovascular Diseases (1) · Coronaviridae Infections (1) · Dyspnea (1) · Heart Failure (1) · Immune System Diseases (1) · Lung Diseases (1) · Myocardial Infarction (1) · Nidovirales Infections (1) · Pneumonia, Viral (1) · Pulmonary Edema (1) · RNA Virus Infections (1)
Infections (7) · Coronaviridae Infections (6) · Nidovirales Infections (6) · RNA Virus Infections (6) · Virus Diseases (6) · Lung Diseases (3) · Pneumonia, Viral (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Shock (2) · Systemic Inflammatory Response Syndrome (2) · Heart Diseases (1)
Plasma Exchange (1) · VIP-ELP fusion molecule PB1046 (1) · axatilimab (1) · emvododstat (1) · silmitasertib (1)
Celularity Incorporated (1) · Fundacion Clinic per a la Recerca Biomédica (1) · PTC Therapeutics (1) · PhaseBio Pharmaceuticals Inc. (1) · Syndax Pharmaceuticals (1) · UnitedHealth Group (1) · University of Arizona (1)
United States (6) · Spain (2) · Australia (1) · Belgium (1) · Brazil (1) · Colombia (1) · France (1) · Mexico (1) · Poland (1) · Portugal (1) · South Africa (1)
Corey Casper, MD MPH (1) · Deneen Vojta, MD (1) · Quintus Ngumah, OD, PhD (1)